Drug Trial Radar · NCT06411249
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
302
Actual
Start
Jun 6, 2024
Primary completion
Jun 29, 2027
Study completion Jul 30, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.
Conditions
- Systemic Lupus Erythematosus
Interventions
Belimumab (GSK1550188)Biological
GSK1550188 will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52Time frame: At Week 52
Locations
104 sites in 11 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Anniston, Alabama
GSK Investigational Site
Flagstaff, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Covina, California
GSK Investigational Site
Fontana, California
GSK Investigational Site
Fullerton, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Mission Hills, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Temecula, California
GSK Investigational Site
Tujunga, California
GSK Investigational Site
Van Nuys, California
GSK Investigational Site
Van Nuys, California
GSK Investigational Site
Whittier, California
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Tamarac, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Morton Grove, Illinois
GSK Investigational Site
Rockford, Illinois
GSK Investigational Site
Baton Rouge, Louisiana
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Lansing, Michigan
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Duncansville, Pennsylvania
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Baytown, Texas
GSK Investigational Site
Colleyville, Texas
GSK Investigational Site
Fort Worth, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Katy, Texas
GSK Investigational Site
Plano, Texas
GSK Investigational Site
Danville, Virginia
GSK Investigational Site
Glendale, Wisconsin
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.